Teva Pharmaceuticals
TEVA
436 hedge funds and large institutions have $5.76B invested in Teva Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 127 increasing their positions, 135 reducing their positions, and 58 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
42% more capital invested
Capital invested by funds: $4.07B → $5.76B (+$1.69B)
33% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 58
2% more funds holding
Funds holding: 427 → 436 (+9)
0.32% less ownership
Funds ownership: 54.15% → 53.83% (-0.32%)
6% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 135
40% less call options, than puts
Call options by funds: $354M | Put options by funds: $586M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$75M |
| 2 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$73.7M |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$47.7M |
| 4 |
Two Sigma Investments
New York
|
+$21.3M |
| 5 |
JP Morgan Chase
New York
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$192M |
| 2 |
Renaissance Technologies
New York
|
-$42M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$36.1M |
| 4 |
Jane Street
New York
|
-$26.1M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$22.8M |
TEVA Hedge Fund Activity: Q4 2019 in Review
436 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2019, worth a combined $5.76B — up 42% from $4.07B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new TEVA positions and 58 closed out — a net gain of 19 holders — while 127 added to existing stakes and 135 trimmed.
The largest buyer was Menora Mivtachim Holdings, opening a new position worth an estimated $75M. The largest seller was Franklin Resources, cutting an estimated $192M.
- 436 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2019, up from 427 in Q3 2019.
- Funds reported $5.76B of Teva Pharmaceuticals stock for Q4 2019, up 42% quarter-over-quarter.
- 77 funds opened new Teva Pharmaceuticals positions in Q4 2019 and 58 closed out, a net change of +19 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2019 was Menora Mivtachim Holdings, an estimated $75M added.
- The largest Teva Pharmaceuticals seller in Q4 2019 was Franklin Resources, an estimated $192M sold.
Based on aggregated 13F filings for Q4 2019.